Antimicrobial Resistance Surveillance Market by Component, End-User

Description

List of Tables

The Antimicrobial Resistance Surveillance Market was valued at USD 5.60 billion in 2023, expected to reach USD 5.96 billion in 2024, and is projected to grow at a CAGR of 6.49%, to USD 8.71 billion by 2030.

Antimicrobial resistance (AMR) surveillance refers to the systematic collection, analysis, and interpretation of data related to the prevalence and patterns of antimicrobial resistance in pathogens. This critical public health tool is necessary to monitor how resistance is spreading, to guide the use of antimicrobial agents, and to inform on the development of new drugs and treatment protocols. AMR surveillance is applied within healthcare facilities, community settings, and through national health systems, with an end-user scope that includes hospitals, diagnostic labs, research institutes, pharmaceutical companies, and governmental bodies. Market growth in this field is influenced by the increasing prevalence of drug-resistant infections, the urgent need for novel antimicrobials due to the depletion of effective options, and supportive government policies alongside global initiatives that emphasize collaborative strategies against AMR. Technological advancements, like rapid diagnostic tests, and increased funding for R&D by both public and private sectors present significant opportunities. Additionally, AI and big data analytics are offering potential avenues for innovation, driving forward surveillance methodologies. However, the market faces challenges, including high costs associated with novel diagnostic technologies and limited expertise in low-resource settings, which represents a barrier to widespread implementation. Furthermore, discrepancies in data due to varying standards and surveillance capacities across nations complicate global efforts. For business growth, innovation should focus on enhancing cost-effectiveness and accessibility of rapid diagnostics, exploiting AI for predictive modeling, and expanding point-of-care testing. Continuous collaboration with international health organizations can also provide strategic advantages. The market's nature is dynamic, reflecting an urgent demand for solutions, pushing stakeholders to prioritize adaptation, cross-border collaboration, and the integration of innovative technologies that can outpace rapidly evolving microbial threats.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.60 billion
Estimated Year [2024]	USD 5.96 billion
Forecast Year [2030]	USD 8.71 billion
CAGR (%)	6.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antimicrobial Resistance Surveillance Market

The Antimicrobial Resistance Surveillance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing prevalence of infections caused by pathogens
- Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
Market Restraints
- High cost associated with antimicrobial resistance surveillance
Market Opportunities
- Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
- Increasing regulatory approvals of diagnostics products worldwide
Market Challenges
- Lack of standardized methods and guidelines for AMR surveillance

Porter's Five Forces: A Strategic Tool for Navigating the Antimicrobial Resistance Surveillance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antimicrobial Resistance Surveillance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antimicrobial Resistance Surveillance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antimicrobial Resistance Surveillance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antimicrobial Resistance Surveillance Market

A detailed market share analysis in the Antimicrobial Resistance Surveillance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antimicrobial Resistance Surveillance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antimicrobial Resistance Surveillance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antimicrobial Resistance Surveillance Market

A strategic analysis of the Antimicrobial Resistance Surveillance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antimicrobial Resistance Surveillance Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accelerate Diagnostics, Inc., acquired by bioMerieux SA, Agilent Technologies, Inc., Becton, Dickinson and Company, bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Hologic, Inc., Illumina, Inc., Johnson & Johnson Services Inc., Liofilchem S.r.l., Luminex Corporation by DiaSorin S.p.A., Merck & Co., Inc., Novo Holdings A/S, OpGen, Inc., Pfizer Inc., QIAGEN GmbH, Sanofi S.A., Thermo Fisher Scientific Inc., Venatorx Pharmaceuticals, Inc., Viatris Inc., Vivli Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Antimicrobial Resistance Surveillance Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Component, market is studied across Diagnostic Kits, Diagnostic Systems, Services, and Software.
Based on End-User, market is studied across Hospitals and Research & Academic Institutes.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-CF6C60CF95A8

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of infections caused by pathogens
  - 5.1.1.2. Rising government initiatives to improve the quality of diagnostics and point-of-care diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with antimicrobial resistance surveillance
- 5.1.3. Opportunities
  - 5.1.3.1. Growing demand for advanced diagnostic solutions to manage Antimicrobial Resistance (AMR) infections
  - 5.1.3.2. Increasing regulatory approvals of diagnostics products worldwide
- 5.1.4. Challenges
  - 5.1.4.1. Lack of standardized methods and guidelines for AMR surveillance
5.2. Market Segmentation Analysis
- 5.2.1. Component: Significant role of diagnostic kits in offering rapid detection of specific resistance markers at relatively lower costs
- 5.2.2. End-User: Increasing incidence of hospital-acquired infections developed necessities for next generation antimicrobial resistance (AMR) surveillance
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Antimicrobial Resistance Surveillance Market, by Component

6.1. Introduction
6.2. Diagnostic Kits
6.3. Diagnostic Systems
6.4. Services
6.5. Software

7. Antimicrobial Resistance Surveillance Market, by End-User

7.1. Introduction
7.2. Hospitals
7.3. Research & Academic Institutes

8. Americas Antimicrobial Resistance Surveillance Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Antimicrobial Resistance Surveillance Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Antimicrobial Resistance Surveillance Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. AI-Driven AMRx Tool Advanced Antimicrobial Resistance Diagnosis and Treatment, Enhancing Accuracy and Patient Outcomes
- 11.3.2. Visby Medical Secures USD 1.8 Million to Advance Portable Gonorrhea Test with Antibiotic Resistance Screening
- 11.3.3. Novo Holdings Strengthens Fight Against Drug-Resistant Infections by Acquiring Paratek Pharmaceuticals
- 11.3.4. AMR Action Fund Expands Investment Efforts to Tackle Antibiotic Resistance
11.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Abbott Laboratories
2. Accelerate Diagnostics, Inc.
3. acquired by bioMerieux SA
4. Agilent Technologies, Inc.
5. Becton, Dickinson and Company
6. bioMerieux SA
7. Bruker Corporation
8. Cepheid by Danaher Corporation
9. F. Hoffmann-La Roche Ltd
10. GlaxoSmithKline PLC
11. Hologic, Inc.
12. Illumina, Inc.
13. Johnson & Johnson Services Inc.
14. Liofilchem S.r.l.
15. Luminex Corporation by DiaSorin S.p.A.
16. Merck & Co., Inc.
17. Novo Holdings A/S
18. OpGen, Inc.
19. Pfizer Inc.
20. QIAGEN GmbH
21. Sanofi S.A.
22. Thermo Fisher Scientific Inc.
23. Venatorx Pharmaceuticals, Inc.
24. Viatris Inc.
25. Vivli Inc.
26. Wolters Kluwer N.V.